Last reviewed · How we verify
Antiarrhythmic drug
Antiarrhythmic drugs suppress abnormal electrical activity in the heart to restore normal heart rhythm.
Antiarrhythmic drugs suppress abnormal electrical activity in the heart to restore normal heart rhythm. Used for Atrial fibrillation, Ventricular arrhythmias, Supraventricular tachycardia.
At a glance
| Generic name | Antiarrhythmic drug |
|---|---|
| Also known as | Class I or III, Statin Therapy, Anticoagulants, Amiodarone, Sotalol, medical treatment of atrial flutter |
| Sponsor | Hospital San Carlos, Madrid |
| Drug class | Antiarrhythmic agent |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Antiarrhythmics work through various mechanisms depending on their class: some block sodium channels (Class I), others block beta-adrenergic receptors (Class II), some prolong repolarization (Class III), and others block calcium channels (Class IV). By modulating cardiac electrical conduction and refractoriness, these drugs prevent or terminate arrhythmias and maintain normal sinus rhythm.
Approved indications
- Atrial fibrillation
- Ventricular arrhythmias
- Supraventricular tachycardia
- Arrhythmia prevention and management
Common side effects
- Bradycardia
- Hypotension
- Dizziness
- Nausea
- Proarrhythmic effects
- Fatigue
Key clinical trials
- Non-Invasive Programmed Stimulation (NIPS) to Guide the Subsequent VT Therapeutic Strategies (NA)
- The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients (PHASE4)
- Acupuncture for Preventing Atrial Arrhythmia Recurrence After Ablation (NA)
- Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia (NA)
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance (PHASE4)
- Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial Fibrillation (NA)
- Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antiarrhythmic drug CI brief — competitive landscape report
- Antiarrhythmic drug updates RSS · CI watch RSS
- Hospital San Carlos, Madrid portfolio CI